Cencora, Inc. (LON:0HF3)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 37.59B -9.8% |
| Revenue (ttm) | 248.91B +5.9% |
| Net Income | 1.93B +50.5% |
| EPS | 9.89 +52.0% |
| Shares Out | n/a |
| PE Ratio | 19.48 |
| Forward PE | 14.19 |
| Dividend | 1.72 (0.66%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | n/a |
| Average Volume | 451 |
| Open | 260.93 |
| Previous Close | 260.57 |
| Day's Range | 260.93 - 260.93 |
| 52-Week Range | 245.77 - 381.28 |
| Beta | 0.65 |
| RSI | 26.44 |
| Earnings Date | May 6, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
Cencora price target lowered to $331 from $429 at Wells Fargo
Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora (COR) to $331 from $429 and keeps an Overweight rating on the shares. The firm says that the…
Cencora price target lowered to $342 from $400 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cencora (COR) to $342 from $400 and keeps an Overweight rating on the shares.
Cencora price target lowered to $339 from $420 at Baird
Baird lowered the firm’s price target on Cencora (COR) to $339 from $420 and keeps an Outperform rating on the shares.
Cencora price target lowered to $300 from $360 at Evercore ISI
Evercore ISI lowered the firm’s price target on Cencora (COR) to $300 from $360 and keeps an Outperform rating on the shares.
Cencora price target raised to $412 from $410 at UBS
UBS raised the firm’s price target on Cencora (COR) to $412 from $410 and keeps a Buy rating on the shares.
Cencora price target lowered to $355 from $405 at Citi
Citi lowered the firm’s price target on Cencora (COR) to $355 from $405 and keeps a Buy rating on the shares. The company reported “disappointing” U.S. healthcare results in fiscal…
Cencora reports Q2 adjusted EPS $4.75, consensus $4.73
Reports Q2 revenue $78.4B, consensus $81.04B. “Cencora (COR) delivered solid results in our second quarter as our team members continued to execute to meet the needs of our customers,” said…
Cencora raises FY26 adjusted EPS view to $17.65-$17.90 from $17.45-$17.75
FY26 consensus $17.61. Sees FY26 revenue growth 4%-6% vs. 7%-9% prior, consensus $345.81B.
Cencora Earnings Call Transcript: Q2 2026
Adjusted EPS grew 7.5% and operating income rose in both core segments, despite revenue headwinds from price reductions, customer losses, and faster biosimilar conversions. Full-year EPS guidance was raised, with strong cash flow and resumed share buybacks supporting long-term growth.
Cencora raises annual profit forecast despite quarterly miss
Cencora reported second-quarter results below Wall Street estimates on Wednesday but raised its annual profit forecast, betting on a steady demand for specialty medicines.
Cencora Reports Fiscal 2026 Second Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. ...
Cencora initiated with a Market Perform at William Blair
William Blair initiated coverage of Cencora (COR) with a Market Perform rating. Cencora is positioned to capitalize on a structurally favorable demand backdrop supported by demographic tailwinds and r...
CareMetx Acquires U.S.-based Patient Services and Free Goods Pharmacy Operations from Cencora, Significantly Expanding Its Patient Access Platform
As demand for technology-forward patient services accelerates, combined organization positions CareMetx to deliver greater innovation for biopharma clients. As demand for technology-forward patient se...
Cencora price target lowered to $360 from $420 at Evercore ISI
Evercore ISI lowered the firm’s price target on Cencora (COR) to $360 from $420 and keeps an Outperform rating on the shares. The firm made several price target adjustments and…
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening...
Cencora to buy retina business of EyeSouth Partners for $1.1 billion
Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit.
Cencora signs agreement to acquire EyeSouth Partners’ retina business for $1.1B
Cencora (COR) announced the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of Ey...
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of t...
Cencora CFO James Cleary to retire
Cencora (COR) announced that James Cleary will retire as executive VP and CFO effective June 30. Cencora has engaged an executive search firm to identify and evaluate potential successors from…
Cencora backs FY26 adjusted EPS view $17.45-$17.75, consensus $17.62
The company said, “Cencora (COR) is also reaffirming its previously issued adjusted diluted EPS guidance range of $17.45 to $17.75 for fiscal year 2026.”
Cencora Announces Financial Leadership Transition
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora ...
Cencora Transcript: Leerink Global Healthcare Conference 2026
Strong U.S. segment growth and expanded MSO capabilities drove increased guidance, while strategic acquisitions and divestitures enhanced operational focus. Specialty and generics markets remain healthy, with ongoing investments in synergies, contracting, and customer relationships supporting long-term growth.
Cencora Transcript: Barclays 28th Annual Global Healthcare Conference
Strong U.S. segment growth and raised guidance followed the OneOncology acquisition, with the MSO strategy and specialty focus driving long-term targets. Generic and biosimilar pipelines, stable pricing, and effective management of IRA changes support a positive outlook.
Cencora price target raised to $380 from $360 at BofA
BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $380 from $360 and keeps a Neutral rating on the shares. McKesson (MCK) “quietly” received a new…
Cencora Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed by majority vote. Financial results showed 16% growth in adjusted operating income and EPS, with new acquisitions and a $1 billion investment commitment announced.